ATP6V0D2

Across TCGA pan-cancer cohorts, ATP6V0D2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ATP6V0D2 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ATP6V0D2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP6V0D2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where ATP6V0D2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.238	0.804	<.001	32	view →
CCRCC	DFS	Median	II,III,IV	0.829	0.546	.012	6	view →
LSCC	OS	Median	All	0.733	1.000	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ATP6V0D2–LUAD (DFS)

Open the LUAD breakdown →